Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI may replace invasive biopsies for urinary tract cancer diagnosis

NCT ID NCT07252882

Diagnosis Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to see if a special MRI scan can accurately diagnose invasive upper urinary tract tumors. About 178 adults with suspicious findings on a CT scan will receive an MRI, and the results will be compared to standard biopsy or follow-up CT. If successful, MRI could offer a non-invasive way to diagnose these cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age with a suspected upper urinary tract tumour based on the presence of a suspicious lesion on a uro-computed tomography scan * Have given free, informed and signed consent * Be affiliated to a social security scheme Exclusion Criteria: * Renal failure not allowing the injection of iodinated contrast media (Glomerular filtration rate \<30mL/min) * Subject under legal protection (guardianship or curatorship) * Pregnant or breastfeeding woman * Person participating in another research study or having participated in a protocol with an exclusion period still in progress at inclusion * Contraindication to magnetic resonance imaging (patient with non-magnetic resonance imaging compatible equipment, claustrophobia preventing magnetic resonance imaging) * Acide gadoteric hypersensibility

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Magnetic resonance imaging (MRI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm malignant urinary system neoplasm renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Magnetic resonance imaging (MRI) Urologic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Toulouse

    Toulouse, France, 31059, France

  • Clinique Beau Soleil

    Montpellier, France, 34070, France

  • Clinique La Croix du Sud

    Quint-Fonsegrives, France, 31130, France

  • Clinique Pasteur

    Toulouse, France, 31076, France

  • Hôpital Claude Huriez

    Lille, France, 59037, France

  • Hôpital Européen Georges Pompidou

    Paris, France, 75015, France

  • Hôpital Lapeyronie

    Montpellier, France, 34295, France

  • Hôpital Pellegrin

    Bordeaux, France, 33000, France

  • Hôpital Saint-Louis

    Paris, France, 75010, France

  • Hôpital de la Pitié Salpêtrière

    Paris, France, 75013, France

  • Institut Paoli Calmettes

    Marseille, France, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.